ARQT - NASDAQ
Arcutis Biotherapeutics, Inc.
$21.35
-0.56%Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
At a Glance
Live SnapshotArcutis Biotherapeutics, Inc. Management Team
Mr. Rajvir Madan
Chief Digital & Technology Officer
Ms. Latha Vairavan
Chief Financial Officer
Dr. Bhaskar Chaudhuri Ph.D.
Co-Founder & Independent Director
Compensation
$65,000
Mr. Larry Todd Edwards
Executive Vice President & Chief Commercial Officer
Compensation
$833,908
Dr. Patrick E. Burnett M.D., Ph.D.
Executive Vice President & Chief Medical Officer
Compensation
$814,766
Ms. Amanda Sheldon
Head of Corporate Communications
Mr. Brian Schoelkopf
Head of Investor Relations
Mr. Todd Franklin Watanabe M.A.
President, Chief Executive Officer & Director
Compensation
$1,230,634
Mr. Kent Taylor
Senior Vice President of Sales
Mr. Masaru Matsuda Esq., J.D.
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$749,940
Ms. Courtney Barton
Vice President and Chief Compliance Officer & Privacy Officer
Mr. Steve Arias
Vice President of Compliance & Privacy
Arcutis Biotherapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $65K and sold $10.83M worth of ARQT shares, resulting in $10.76M of net selling activity.
3 Months
0
0.00
25.2K
588.39K
-588K
-$588K
3-6 Months
0
0.00
85.4K
2.26M
-2.3M
-$2.26M
6-9 Months
0
0.00
234.4K
6.08M
-6.1M
-$6.08M
9-12 Months
4.9K
64.86K
126.7K
1.91M
-1.8M
-$1.84M
Top Buyers
Heron Patrick J
Director
$65K
Top Sellers
Watanabe Todd
Director, Officer: See Remarks
$3.46M
Welgus Howard G.
Director
$1.99M
Burnett Patrick
Officer: See Remarks
$1.52M
Matsuda Masaru
Officer: See Remarks
$1.13M
Leonard Keith R
Director
$997K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $10.76M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ARQT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | April 26, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 18, 2023 | April 18, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 19, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 09, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.